

Pedro Isaacsson Velho

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3888412/pedro-isaacsson-velho-publications-by-citations.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30 papers	544 citations	13 h-index	23 g-index
31 ext. papers	862 ext. citations	4.9 avg, IF	4.12 L-index

#	Paper	IF	Citations
30	Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. <i>European Urology</i> , 2019 , 75, 378-382	10.2	87
29	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. <i>Prostate</i> , 2018 , 78, 401-407	4.2	68
28	-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , 2020 , 4, 370-381	3.6	66
27	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 475-486	3.8	52
26	Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. <i>European Urology</i> , 2019 , 76, 170-176	10.2	49
25	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 1208-1216	6.4	37
24	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>European Urology</i> , 2020 , 78, 652-656	10.2	27
23	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020 , 77, 14-21	10.2	26
22	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021 , 4, 447-455	6.7	20
21	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020 , 136, 16-24	7.5	16
20	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019 , 79, 1597-1603	4.2	14
19	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021 , 80, 632-640	10.2	14
18	Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. <i>Prostate</i> , 2019 , 79, 1572-1579	4.2	13
17	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021 , 26, e270-e278	5.7	12
16	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020 , 204, 63-70	2.5	11
15	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 464-472	6.7	9
14	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	7

13	Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 811-822	5.9	3
12	Clinical and genomic features of SPOP-mutant prostate cancer. <i>Prostate</i> , 2021 , 82, 260	4.2	3
11	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021 , 128, 196-205	5.6	3
10	Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020 , 26, 2489-2497	2.6	2
9	Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2021 , 81, 572-579	4.2	1
8	Detection of Early Progression with F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1270-1273	8.9	1
7	New approaches to targeting the androgen receptor pathway in prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021 , 19, 228-240	0.6	1
6	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
5	Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
4	The development of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2021 , 16, 217-226	6.2	0
3	Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 329-329	2.2	
2	Genomic analysis and clinical outcomes of Primary Gleason Pattern 5 (PG5) prostate cancer (PCa) treated with radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 54-54	2.2	
1	WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5068-5068	2.2	